Published in Can J Urol on April 01, 2016
The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity. Nature (2012) 31.78
Sipuleucel-T immunotherapy for castration-resistant prostate cancer. N Engl J Med (2010) 29.75
Mapping and analysis of chromatin state dynamics in nine human cell types. Nature (2011) 24.37
Efficient design and assembly of custom TALEN and other TAL effector-based constructs for DNA targeting. Nucleic Acids Res (2011) 16.53
The long-term effect of doxazosin, finasteride, and combination therapy on the clinical progression of benign prostatic hyperplasia. N Engl J Med (2003) 11.25
Prevalence of chronic kidney disease in China: a cross-sectional survey. Lancet (2012) 10.53
Overdiagnosis due to prostate-specific antigen screening: lessons from U.S. prostate cancer incidence trends. J Natl Cancer Inst (2002) 9.45
Early detection of prostate cancer: AUA Guideline. J Urol (2013) 9.14
The genome of the mesopolyploid crop species Brassica rapa. Nat Genet (2011) 8.23
Long-term functional outcomes after treatment for localized prostate cancer. N Engl J Med (2013) 7.95
Risk of adverse outcomes associated with concomitant use of clopidogrel and proton pump inhibitors following acute coronary syndrome. JAMA (2009) 7.78
Exercise is associated with reduced risk for incident dementia among persons 65 years of age and older. Ann Intern Med (2006) 7.14
Prdm16 determines the thermogenic program of subcutaneous white adipose tissue in mice. J Clin Invest (2010) 6.96
Guideline for the management of clinically localized prostate cancer: 2007 update. J Urol (2007) 6.73
Loss of stearoyl-CoA desaturase-1 function protects mice against adiposity. Proc Natl Acad Sci U S A (2002) 6.00
Five-year outcomes after prostatectomy or radiotherapy for prostate cancer: the prostate cancer outcomes study. J Natl Cancer Inst (2004) 5.84
Survival after initial diagnosis of Alzheimer disease. Ann Intern Med (2004) 5.52
Prostate cancer and the Will Rogers phenomenon. J Natl Cancer Inst (2005) 5.10
Guideline for the management of nonmuscle invasive bladder cancer (stages Ta, T1, and Tis): 2007 update. J Urol (2007) 5.03
Update on AUA guideline on the management of benign prostatic hyperplasia. J Urol (2011) 5.01
Bile acids lower triglyceride levels via a pathway involving FXR, SHP, and SREBP-1c. J Clin Invest (2004) 4.65
Comparative epigenomic analysis of murine and human adipogenesis. Cell (2010) 4.08
Incidence of death and acute myocardial infarction associated with stopping clopidogrel after acute coronary syndrome. JAMA (2008) 4.06
Brahma links the SWI/SNF chromatin-remodeling complex with MeCP2-dependent transcriptional silencing. Nat Genet (2005) 3.98
Mortality after radical prostatectomy or external beam radiotherapy for localized prostate cancer. J Natl Cancer Inst (2013) 3.81
Effect of age, tumor risk, and comorbidity on competing risks for survival in a U.S. population-based cohort of men with prostate cancer. Ann Intern Med (2013) 3.74
Adaptive thermogenesis in adipocytes: is beige the new brown? Genes Dev (2013) 3.74
The oncogenic properties of mutant p110alpha and p110beta phosphatidylinositol 3-kinases in human mammary epithelial cells. Proc Natl Acad Sci U S A (2005) 3.72
Molecular mechanisms of cancer development in obesity. Nat Rev Cancer (2011) 3.65
Patient-specific induced pluripotent stem cells as a model for familial dilated cardiomyopathy. Sci Transl Med (2012) 3.53
Systematic dissection and optimization of inducible enhancers in human cells using a massively parallel reporter assay. Nat Biotechnol (2012) 3.52
Circulating microRNAs, miR-21, miR-122, and miR-223, in patients with hepatocellular carcinoma or chronic hepatitis. Mol Carcinog (2010) 3.44
Ureteroenteric anastomotic strictures after radical cystectomy-does operative approach matter? J Urol (2012) 3.30
A comparison of the incidence and location of positive surgical margins in robotic assisted laparoscopic radical prostatectomy and open retropubic radical prostatectomy. J Urol (2007) 3.26
Comparative effectiveness of prostate cancer treatments: evaluating statistical adjustments for confounding in observational data. J Natl Cancer Inst (2010) 3.24
Complete genome sequence of Yersinia pestis strain 91001, an isolate avirulent to humans. DNA Res (2004) 2.95
Factors associated with satisfaction with prostate cancer care: results from Cancer of the Prostate Strategic Urologic Research Endeavor (CaPSURE). BJU Int (2012) 2.88
Follow-up for Clinically Localized Renal Neoplasms: AUA Guideline. J Urol (2013) 2.76
Inefficient reprogramming of fibroblasts into cardiomyocytes using Gata4, Mef2c, and Tbx5. Circ Res (2012) 2.74
Quantifying the role of PSA screening in the US prostate cancer mortality decline. Cancer Causes Control (2007) 2.69
Intrathoracic impedance monitoring in patients with heart failure: correlation with fluid status and feasibility of early warning preceding hospitalization. Circulation (2005) 2.66
The prostate cancer conundrum revisited: treatment changes and prostate cancer mortality declines. Cancer (2012) 2.61
Molecular characterization of the role of orphan receptor small heterodimer partner in development of fatty liver. Hepatology (2007) 2.53
Preoperative nutritional status is an important predictor of survival in patients undergoing surgery for renal cell carcinoma. Eur Urol (2011) 2.51
Stearoyl-CoA desaturase 1 deficiency increases fatty acid oxidation by activating AMP-activated protein kinase in liver. Proc Natl Acad Sci U S A (2004) 2.48
Randomized trial of lapatinib versus placebo added to paclitaxel in the treatment of human epidermal growth factor receptor 2-overexpressing metastatic breast cancer. J Clin Oncol (2013) 2.44
Why do men choose one treatment over another?: a review of patient decision making for localized prostate cancer. Cancer (2006) 2.42
Zfp423 expression identifies committed preadipocytes and localizes to adipose endothelial and perivascular cells. Cell Metab (2012) 2.41
Early and late perioperative outcomes following radical cystectomy: 90-day readmissions, morbidity and mortality in a contemporary series. J Urol (2010) 2.39
A critical role of IFNgamma in priming MSC-mediated suppression of T cell proliferation through up-regulation of B7-H1. Cell Res (2008) 2.38
The association between diffusion of the surgical robot and radical prostatectomy rates. Med Care (2011) 2.38
A comparative analysis of five methods of determining corneal refractive power in eyes that have undergone myopic laser in situ keratomileusis. Ophthalmology (2002) 2.37
Primary treatments for clinically localised prostate cancer: a comprehensive lifetime cost-utility analysis. BJU Int (2012) 2.37
Castration-resistant prostate cancer: AUA Guideline. J Urol (2013) 2.36
Immediate effects of the initial FDA notification on the use of surgical mesh for pelvic organ prolapse surgery in medicare beneficiaries. Neurourol Urodyn (2012) 2.35
Trends in stress urinary incontinence inpatient procedures in the United States, 1979-2004. Am J Obstet Gynecol (2009) 2.33
Multiobjective optimization design of a fractional order PID controller for a gun control system. ScientificWorldJournal (2013) 2.33
Abnormal calcium handling properties underlie familial hypertrophic cardiomyopathy pathology in patient-specific induced pluripotent stem cells. Cell Stem Cell (2013) 2.33
NCCN clinical practice guidelines in oncology: prostate cancer early detection. J Natl Compr Canc Netw (2010) 2.31
Gene expression profiles of CD34+ cells in myelodysplastic syndromes: involvement of interferon-stimulated genes and correlation to FAB subtype and karyotype. Blood (2006) 2.29
What if I don't treat my PSA-detected prostate cancer? Answers from three natural history models. Cancer Epidemiol Biomarkers Prev (2011) 2.25
Race/ethnicity, obesity, health related behaviors and the risk of symptomatic benign prostatic hyperplasia: results from the prostate cancer prevention trial. J Urol (2007) 2.24
Long-term effects of finasteride on prostate specific antigen levels: results from the prostate cancer prevention trial. J Urol (2005) 2.24
The p110alpha isoform of PI3K is essential for proper growth factor signaling and oncogenic transformation. Proc Natl Acad Sci U S A (2006) 2.23
Oncologic efficacy of CT-guided percutaneous radiofrequency ablation of renal cell carcinomas. AJR Am J Roentgenol (2007) 2.20
ICUD-EAU International Consultation on Bladder Cancer 2012: Radical cystectomy and bladder preservation for muscle-invasive urothelial carcinoma of the bladder. Eur Urol (2012) 2.19
LINGO-1 antagonist promotes spinal cord remyelination and axonal integrity in MOG-induced experimental autoimmune encephalomyelitis. Nat Med (2007) 2.17
Access to information sources and treatment considerations among men with local stage prostate cancer. Urology (2009) 2.15
Reversible and selective amine interactions of [Cd(mu2-N,O-p-NH2C6H4SO3)2(H2O)2]n. Dalton Trans (2004) 2.13
Microbiota of the seminal fluid from healthy and infertile men. Fertil Steril (2013) 2.10
Polyethylenimine-based siRNA nanocomplexes reprogram tumor-associated dendritic cells via TLR5 to elicit therapeutic antitumor immunity. J Clin Invest (2009) 2.06
Impact of PSA screening on the incidence of advanced stage prostate cancer in the United States: a surveillance modeling approach. Med Decis Making (2008) 2.06
A thorough pelvic lymph node dissection in presence of positive margins associated with better clinical outcomes in radical cystectomy patients. Urology (2009) 2.06
Androgen-deprivation therapy in prostate cancer and cardiovascular risk: a science advisory from the American Heart Association, American Cancer Society, and American Urological Association: endorsed by the American Society for Radiation Oncology. CA Cancer J Clin (2010) 2.05
Tau accumulation activates the unfolded protein response by impairing endoplasmic reticulum-associated degradation. J Neurosci (2013) 2.04
A self-assembling nanoparticle for paclitaxel delivery in ovarian cancer. Biomaterials (2009) 2.04
TRPV4 is a regulator of adipose oxidative metabolism, inflammation, and energy homeostasis. Cell (2012) 2.03
Effect of preoperative nutritional deficiency on mortality after radical cystectomy for bladder cancer. J Urol (2010) 2.03